Suda Pharmaceuticals

AU: SUD

Market CapAU$25.5m

Last Close AU$0.05

SUDA Pharmaceuticals is a drug delivery company focusing on developing oro-mucosal spray versions of established medicines. It has the rights to ZolpiMist, the spray version of Ambien for insomnia, outside of North America.

More Suda Pharmaceuticals content >

Investment summary

SUDA Pharmaceuticals has historically focused on reformulating established drugs into oro-mucosal spray formulations for better bioavailability. Its lead commercial product is ZolpiMist, an oro-mucosal spray version of Ambien for the treatment of insomnia that is partnered in certain regions with Teva and Mitsubishi Tanabe. SUDA recently in-licensed an invariant natural killer T (iNKT) cell therapy platform that can be used in conjunction with chimeric antigen receptors to target blood cancers. There are a number of potential benefits of CAR-iNKT, including the prospect of being an allogeneic ‘off-the-shelf’ therapy, significantly simplifying the manufacture of the therapy and its delivery to patients. The therapy is expected to enter the clinic in 12–24 months and could be transformative for the company.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 1.2 (1.9) (2.4) (1.54) N/A N/A
2020A 0.5 (4.1) (4.7) (2.81) N/A N/A
2021E 0.5 (3.6) (4.3) (1.29) N/A N/A
2022E 1.0 (5.9) (6.6) (1.37) N/A N/A
Industry outlook

SUDA is targeting very large markets including insomnia (through ZolpiMist) and various cancers (through the CAR-iNKT programme as well as anagrelide).

Last updated on 23/07/2021
Content on Suda Pharmaceuticals
SUDA Pharmaceuticals – Half-year update
Healthcare | Update | 11 March 2021
pexels-photo-4021779
Suda Pharmaceuticals – A TGA approval and a capital raise
Healthcare | Update | 3 September 2020
pexels-photo-4021779
View more
Register to receive research on Suda Pharmaceuticals as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 6.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 1.9 23.3 96.3
Relative* 1.0 17.7 58.7
52-week high/low A$0.1/A$0.0
*% relative to local index
Key management
Michael Baker CEO and Managing Director